Tags
- A
- AbbVie Inc.
- Abdominal
- Abdominal pain
- Active ingredient
- Adult
- Adverse
- Adverse effect
- Alpha
- An
- Anorexia
- Antibody
- Antibody-drug conjugate
- Apoptosis
- Appetite
- Approval
- Arrest
- Arthralgia
- Aspartate transaminase
- Aspartic acid
- Attached
- Authorization
- BIND
- Binding
- Blurred
- Blurred vision
- Cancer
- Cancer Cell
- Cell
- Cell Cycle
- Cell cycle arrest
- Cell death
- Cells
- Chemotherapy
- Cleavage
- Commission
- Committee for Medicinal Products for Human Use
- Concentrate
- Conjugate
- Consensus
- Constipation
- Containment
- Cycle
- Death
- Demonstration
- Determine
- Determined
- Deutschland
- Development
- Diarrhea
- Disrupt
- Doxorubicin
- Dry
- Dry eye syndrome
- Effect
- Efficacy
- Ema Backs
- Ema Ha
- Epithelium
- European
- European Commission
- European Medicines Agency
- Experienced
- Expression
- Eye
- Fallopian tube
- Fatigue
- Folate
- Folate receptor
- Folate receptor 1
- Grade
- Grant
- Headache
- Human back
- Human subject research
- ImmunoGen
- Improved
- Indoor Living
- Infusion
- Inhibitor
- Internalization
- Intracellular
- Keratopathy
- latest
- Linker
- Liposome
- Marketing
- Marketing authorization
- Medicine
- Microtubule
- Microtubule network
- Monoclonal
- Monthly meeting
- Most
- National Historic Landmark
- Nausea
- Network
- Neuropathy
- Obligatio consensu
- Orphan
- Orphan drug
- Ovarian cancer
- Ovary
- Paclitaxel
- Pain
- Patient
- PEGylation
- Peripheral
- Peripheral neuropathy
- Peritoneum
- Pharmaceutical drug
- Physician
- Primary
- Primary peritoneal carcinoma
- Product
- Progression-free survival
- Protease
- Proteolysis
- Receptor
- Sérou
- Serous fluid
- Solution
- Substance
- Surface
- Survival
- Survival rate
- Systemic
- Systemic administration
- The Cells
- The european
- Three
- Topotecan
- Transaminase
- Treatment of cancer
- Tube
- Via
- Vision
- Vomiting
- Weakness
- Who